PB 2452

Drug Profile

PB 2452

Alternative Names: MEDI-2452; PB-2452

Latest Information Update: 30 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Class Antibodies
  • Mechanism of Action Platelet aggregation modulators; Purinoceptor P2Y12-modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haemorrhage

Most Recent Events

  • 28 Nov 2017 PhaseBio plans a phase I trial of PB 2452 in the first half of 2018 (Trial profile 700290858)
  • 28 Nov 2017 PB 2452 licensed to PhaseBio Pharmaceuticals worldwide
  • 13 Nov 2014 Preclinical trials in Haemorrhage in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top